Modafinil
Modafinil (Provigil) is a wakefulness-promoting medication for narcolepsy, sleep apnea, and shift-work sleep disorder, widely used off-label as a cognitive enhancer. It is a Schedule IV controlled substance with lower abuse potential than amphetamines, but it is not benign: rare life-threatening skin reactions such as Stevens-Johnson syndrome, cardiovascular and psychiatric effects, and a clinically important interaction that weakens hormonal contraceptives.
Overview
Modafinil is a wakefulness-promoting medication, sold under brand names such as Provigil, approved in the United States to treat excessive sleepiness from narcolepsy, obstructive sleep apnea and shift-work sleep disorder. It is widely used off-label as a smart drug or cognitive enhancer by students and professionals seeking sustained focus. Chemically distinct from amphetamines, it is generally regarded as having lower abuse potential than classical stimulants, but it is still a controlled prescription medicine, not a benign supplement.
Source: MedlinePlus; Wikipedia (CC-BY-SA); DEA
Chemistry & mechanism of action
Modafinil's mechanism is not fully understood, but it acts mainly as an atypical dopamine reuptake inhibitor, modestly increasing dopamine levels in the brain without the rapid, intense surge produced by amphetamine or cocaine. It also affects other wakefulness-regulating systems. This gentler action on dopamine is thought to underlie both its wakefulness-promoting effect and its comparatively low, though not absent, potential for dependence and euphoria.
Source: Wikipedia (CC-BY-SA); DailyMed (FDA label)
Effects
The primary effect is increased wakefulness and reduced fatigue, often with improved alertness and concentration. It generally produces less of the jittery stimulation and intense high associated with amphetamines. Common side effects include headache, nausea, nervousness, anxiety, insomnia and dizziness. Because it can mask fatigue rather than remove the underlying need for sleep, people may push past safe limits without feeling how tired they actually are.
Source: DailyMed (FDA label); MedlinePlus
Risks & harms
Modafinil is generally better tolerated than classical stimulants, but it carries real risks. The most serious are rare but potentially life-threatening skin and hypersensitivity reactions, including Stevens-Johnson syndrome and other severe rashes, which warrant stopping the drug and seeking immediate care at the first sign of a rash, blistering or mouth sores. It can raise heart rate and blood pressure, so caution applies for people with heart conditions. Psychiatric effects including anxiety, agitation, insomnia and, uncommonly, mania or psychotic symptoms have been reported. Although its dependence potential is lower than that of amphetamines, it is not zero, and misuse for cognitive enhancement can disrupt sleep and mood. Modafinil can reduce the effectiveness of hormonal contraceptives, an interaction that is easy to overlook. As with any medication bought outside a pharmacy, products from unregulated online sources may be counterfeit, mislabeled or contaminated, so their identity and purity cannot be assumed. If someone develops a spreading rash, facial swelling, trouble breathing, chest pain or other signs of a severe allergic reaction, treat it as an emergency and call 911. This page has not yet been medically reviewed.
Source: DailyMed (FDA label); MedlinePlus; peer-reviewed literature (NIH/PMC)
Legal status (US)
In the United States, modafinil is a Schedule IV controlled substance, a classification it has held since 1999. Schedule IV denotes an accepted medical use with a low potential for abuse and dependence relative to higher schedules, the same tier as many prescription sedatives. In practice this means modafinil is legal only with a valid prescription, and its prescribing and refills are subject to federal controls. It is likewise a prescription medicine in most other countries. Follow a prescriber's directions and local law; consult DEA and FDA resources for specifics. This page has not yet been medically reviewed.
Source: DEA; US federal law; FDA
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With stimulants, overheating and a racing heart are the main concerns, get somewhere cool, stop any physical activity, and don't take more.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 4236PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 2-benzhydrylsulfinylacetamidePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C15H15NO2SPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)NPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- YFGHCGITMMYXAQ-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- provigil, Provigil, Modiodal, 2-benzhydrylsulfinylacetamide, modaphonil, Modafinilo, (+-)-Modafinil, Modafinilum, Modafinil civ, R Modafinil, 2 BenzhydrylsulfinylacetamidePubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- 3 DOSAGE FORMS AND STRENGTHS 100 mg – white to off white colored capsule shaped tablets debossed with ‘M’ on one side and 100 MG on other side. 200 mg – white topenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Modafinil is an atypical wakefulness-promoting medicine used for excessive sleepiness in conditions such as narcolepsy and shift-work sleep disorder. Unlike the amphetamine-type stimulants it produces alertness and wakefulness with comparatively little of the euphoria, jitteriness or "crash" of the classic stimulants, and it is generally considered to have a lower — though not absent — potential for misuse. Its precise mechanism of action is not fully understood.PubChem CID 4236 + DailyMed label ↗ · retrieved 2026-06-18
- Risks
- Modafinil is usually well tolerated but is not risk-free. It can nudge heart rate and blood pressure upward and cause headache, anxiety and insomnia. Rarely it has been linked to serious skin and hypersensitivity reactions (including Stevens-Johnson syndrome) and to psychiatric effects such as anxiety, mania or, uncommonly, psychosis — more likely at high exposure. A clinically important, non-obvious hazard is that it can make hormonal contraceptives less effective (see interactions).PubChem CID 4236 + DailyMed label ↗ · retrieved 2026-06-18
- Interactions
- Modafinil's most important labelled interaction is with hormonal contraceptives: by inducing the CYP3A4/5 enzyme system it lowers the blood levels of steroidal contraceptives and can make them less effective, so alternative or additional contraception is advised during use and for a period after stopping. The same enzyme induction affects other CYP3A4 substrates such as cyclosporine and certain sedatives, and modafinil's own levels can shift when combined with drugs that inhibit or induce those enzymes.DailyMed §7 Drug Interactions ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 47different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 47 variants
- Strength
- MODAFINIL 100 mg/1
- Imprint
- L233
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Alembic Pharmaceuticals Limited
- Schedule
- CIV
- NDC
- 46708-385 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- M 200 MG
- Color
- white
- Shape
- capsule
- Form
- TABLET
- Labeler
- Bionpharma Inc.
- Schedule
- CIV
- NDC
- 69452-343 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIV
- NDC
- 43353-925 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- L234
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Alembic Pharmaceuticals Limited
- Schedule
- CIV
- NDC
- 46708-386 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- M 100 MG
- Color
- white
- Shape
- capsule
- Form
- TABLET
- Labeler
- Bionpharma Inc.
- Schedule
- CIV
- NDC
- 69452-342 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Proficient Rx LP
- Schedule
- CIV
- NDC
- 71205-544 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIV
- NDC
- 71610-989 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-928 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- PROVIGIL 100 MG
- Color
- white
- Shape
- OVAL
- Form
- TABLET
- Labeler
- CIMA LABS INC.
- Schedule
- CIV
- NDC
- 55253-801 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIV
- NDC
- 71610-991 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- PROVIGIL 200 MG
- Color
- white
- Shape
- OVAL
- Form
- TABLET
- Labeler
- CIMA LABS INC.
- Schedule
- CIV
- NDC
- 55253-802 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-960 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-961 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- 1072
- Color
- WHITE
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Zydus Lifesciences Limited
- Schedule
- CIV
- NDC
- 70771-1051 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- 10 73
- Color
- WHITE
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Zydus Lifesciences Limited
- Schedule
- CIV
- NDC
- 70771-1052 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Proficient Rx LP
- Schedule
- CIV
- NDC
- 82804-126 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- AC 132
- Color
- WHITE
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
- Schedule
- CIV
- NDC
- 23155-604 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- AC 133
- Color
- WHITE
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
- Schedule
- CIV
- NDC
- 23155-605 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- AvPAK
- Schedule
- CIV
- NDC
- 50268-570 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- AvPAK
- Schedule
- CIV
- NDC
- 50268-571 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- MOD 100 APO
- Color
- WHITE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Apotex Corp.
- Schedule
- CIV
- NDC
- 60505-2526 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NuCare Pharmaceuticals,Inc.
- Schedule
- CIV
- NDC
- 68071-5121 ↗ · 2026-06-18
- Strength
- MODAFINIL 200 mg/1
- Imprint
- MOD 200 APO
- Color
- WHITE
- Shape
- OVAL
- Form
- TABLET
- Labeler
- Apotex Corp.
- Schedule
- CIV
- NDC
- 60505-2527 ↗ · 2026-06-18
- Strength
- MODAFINIL 100 mg/1
- Imprint
- 41 J
- Color
- WHITE
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Rising Pharma Holdings, Inc.
- Schedule
- CIV
- NDC
- 57237-154 ↗ · 2026-06-18
Dosage
Pending medical reviewer
